ID   HOS-143B/MTXR8
AC   CVCL_C6V2
DR   Wikidata; Q117704499
RX   PubMed=36480329;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2270 ! 143B
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   PubMed=36480329; DOI=10.1002/adbi.202200194;
RA   Low K., Hills F., Roberts H.C., Stordal B.;
RT   "Establishment and characterization of single and triple-agent
RT   resistant osteosarcoma cell lines.";
RL   Adv. Biol. (Weinh.) 7:e2200194.1-e2200194.13(2023).
//